WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

The 2026 WorkBoat Diesel Directory is here. See engine specs and manufacturer listings for the U.S. commercial fleet. → Download Free

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

33.27 -0.64 (-1.89%)
Streaming Delayed Price Updated: 1:44 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a... 
Via Finterra
Topics ETFs Economy Initial Public Offering
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill
Why Did Roivant Sciences Stock Gain 9% Pre-Market Today? ↗
Via Stocktwits
News headline image
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For Roivant Sciences ↗
 
Via Benzinga
News headline image
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Pulmovant, Inc.
Via GlobeNewswire
News headline image
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
From Roivant Sciences
Via GlobeNewswire
News headline image
The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500.... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Signals Major Pipeline Momentum With Accelerated Timelines ↗
Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs. 
Via Benzinga
News headline image
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant (ROIV) Q2 2026 Earnings Call Transcript ↗
Roivant (ROIV) Q2 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Looking Into Roivant Sciences Ltd's Recent Short Interest ↗
 
Via Benzinga
News headline image
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
6 Analysts Assess Roivant Sciences: What You Need To Know ↗
 
Via Benzinga
News headline image
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17 ↗
Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study,... 
Via Stocktwits
News headline image
Why Roivant Sciences Stock Is Soaring Today ↗
The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug. 
Via The Motley Fool
News headline image
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial ↗
Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results. 
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease ↗
The company is working on a treatment for an autoimmune disease that affects the skin and muscles. 
Via Investor's Business Daily
News headline image
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
From Roivant Sciences
Via GlobeNewswire
News headline image
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Pulmovant, Inc.
Via GlobeNewswire
News headline image
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
From Roivant Sciences
Via GlobeNewswire
News headline image
Why Roivant Sciences Stock Bounced Back on Tuesday ↗
Investors were in a forgiving mood after Monday's dispiriting earnings release. 
Via The Motley Fool
News headline image
Why Roivant Sciences Stock Was Slipping on Monday ↗
The distinctive biotech wasn't a sector favorite as the trading week began. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.